Procter & Gamble Co vs Koninklijke Philips NV — how do they compare? Procter & Gamble Co trades at $150.71 (market cap $349.77B), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Procter & Gamble Co is far larger — about 14.9× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Koninklijke Philips NV for 84 Days on average.
| PG | PHG | |
|---|---|---|
Market Cap | $349.77B | $23.52B |
Volume | 10,055,825 | 1,635,069 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $32.91 |
52-Week Low | $138.10 | $23.81 |
Typical Hold Time | 131 Days | 84 Days |
Enterprise Value | $375.61B | $29.87B |
Dividend Yield | 2.89% | 4.17% |
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, showing resilience amid market volatility. The stock maintains a bullish technical signal with strong moving average support and has consistently beaten earnings estimates in recent quarters. PG demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and steady dividend payments, though valuation multiples remain elevated versus peers.
PG offers stable growth with dividend reliability but faces premium valuation concerns. The 8.3% upside to consensus target of $160.13 suggests moderate potential, while competitive pressures and soft demand outlook present headwinds. Institutional ownership trends show mixed positioning, requiring careful monitoring of margin sustainability and consumer spending patterns.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →